|
 Clarinex is an antihistamine — a type of
medicine that blocks the action of histamine, a natural substance in your
body that is released by your immune system during an allergic reaction.
Antihistamines are often used to help relieve the symptoms of seasonal and
year-round allergies — itchy, watery eyes; sneezing; and runny nose —
caused by exposure to indoor allergens such as dust mite, mold spores, pet
dander, and outdoor allergens caused by pollen from trees, grasses, or
weeds. |
Medication Clarinex Side Effects:
Side effects with Clarinex (desloratadine)
Tablets 5 mg are similar to sugar pill, including sore throat,
dry mouth and fatigue.
Desloratadine may cause side
effects. Tell your doctor if any of these symptoms are severe or
do not go away:
headache, upset stomach, dizziness, sore throat, dry mouth,
muscle pain, extreme tiredness, painful menstruation.
Some side effects can be serious. The following symptom is
uncommon, but if you experience it, call your doctor
immediately:
difficulty breathing
Desloratadine may cause other side effects. Call your doctor if
you have any unusual problems while taking this medication.
Precautions on using Clarinex
Clarinex Tablets 5 mg are
contraindicated in patients who are hypersensitive to this
medication or to any of its ingredients, or to loratadine.
PRECAUTIONS: Carcinogenesis,
Mutagenesis, Impairment of Fertility: The carcinogenic potential
of desloratadine was assessed using loratadine studies. In an
18-month study in mice and a 2-year study in rats, oratadine was
administered in the diet at doses up to 40 mg/kg/day in mice
(estimated desloratadine and desloratadine metabolite exposures
were approximately 3 times the AUC in humans at the recommended
daily oral dose) and 25 mg/kg/day in rats (estimated
desloratadine and desloratadine metabolite exposures were
approximately 30 times the AUC in humans at the recommended
daily oral dose). Male mice given 0 mg/kg/day loratadine had a
significantly higher incidence of hepatocellular tumors
(combined adenomas and carcinomas) than concurrent controls. In
rats, a significantly higher incidence of hepatocellular tumors
(combined adenomas and carcinomas) was observed in males given
10 mg/kg/day and in males and females given 25 mg/kg/day. The
estimated desloratadine and desloratadine metabolite exposures
of rats given 10 mg/kg of loratadine were approximately 7 times
the AUC in humans at the recommended daily oral dose.
The clinical significance of these findings during long-term use
of desloratadine is not known.
|
